Literature DB >> 14567108

[Therapy of atrial fibrillation].

J Tebbenjohanns1, T Korte.   

Abstract

Atrial fibrillation is the most common cardiac arrhythmia in adults. Paroxysmal atrial fibrillation terminates spontaneously, whereas the persistent form terminates only after medical or electrical cardioversion. Permanent atrial fibrillation cannot be cardioverted. Restoration of sinus rhythm can be achieved by antiarrhythmic drugs or electrical cardioversion, both performed under continuous electrocardiographic monitoring. If atrial fibrillation has lasted longer than 48 hours or the precise time of onset cannot be determined, there are two alternative approaches: systemic anticoagulation to achieve an international normalised ratio (INR) of 2.0 to 3.0 for at least three weeks, followed by cardioversion; or cardioversion guided by transesophageal echocadiography indicating the absence of thrombus. Several drugs have been shown to be effective for the maintenance of sinus rhythm. Anticoagulant therapy is mandatory for a minimum of three weeks after cardioversion. In case of drug refractory, highly symptomatic atrial fibrillation the indication for radiofrequency catheter ablation should be discussed, although the value of this new method is still under evaluation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14567108     DOI: 10.1007/s00108-003-0933-5

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  8 in total

Review 1.  Atrial fibrillation.

Authors:  R H Falk
Journal:  N Engl J Med       Date:  2001-04-05       Impact factor: 91.245

Review 2.  [Atrial fibrillation].

Authors:  M G Hennersdorf; C Perings; M Kelm; B E Strauer
Journal:  Internist (Berl)       Date:  2001-12       Impact factor: 0.743

3.  ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology.

Authors:  V Fuster; L E Rydén; R W Asinger; D S Cannom; H J Crijns; R L Frye; J L Halperin; G N Kay; W W Klein; S Lévy; R L McNamara; E N Prystowsky; L S Wann; D G Wyse
Journal:  Eur Heart J       Date:  2001-10       Impact factor: 29.983

4.  A comparison of rate control and rhythm control in patients with atrial fibrillation.

Authors:  D G Wyse; A L Waldo; J P DiMarco; M J Domanski; Y Rosenberg; E B Schron; J C Kellen; H L Greene; M C Mickel; J E Dalquist; S D Corley
Journal:  N Engl J Med       Date:  2002-12-05       Impact factor: 91.245

5.  A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation.

Authors:  Isabelle C Van Gelder; Vincent E Hagens; Hans A Bosker; J Herre Kingma; Otto Kamp; Tsjerk Kingma; Salah A Said; Julius I Darmanata; Alphons J M Timmermans; Jan G P Tijssen; Harry J G M Crijns
Journal:  N Engl J Med       Date:  2002-12-05       Impact factor: 91.245

6.  Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis.

Authors:  R G Hart; O Benavente; R McBride; L A Pearce
Journal:  Ann Intern Med       Date:  1999-10-05       Impact factor: 25.391

7.  Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators.

Authors:  D Roy; M Talajic; P Dorian; S Connolly; M J Eisenberg; M Green; T Kus; J Lambert; M Dubuc; P Gagné; S Nattel; B Thibault
Journal:  N Engl J Med       Date:  2000-03-30       Impact factor: 91.245

8.  Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins.

Authors:  M Haïssaguerre; P Jaïs; D C Shah; A Takahashi; M Hocini; G Quiniou; S Garrigue; A Le Mouroux; P Le Métayer; J Clémenty
Journal:  N Engl J Med       Date:  1998-09-03       Impact factor: 91.245

  8 in total
  1 in total

1.  [Adequate anticoagulation in atrial fibrillation].

Authors:  T Heimig; A Altiner; J Tebbenjohanns
Journal:  Internist (Berl)       Date:  2003-10       Impact factor: 0.743

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.